Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06389513

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Phase IV Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
3,011 (actual)
Sponsor
CanSino Biologics Inc. · Industry
Sex
All
Age
3 Months – 3 Months
Healthy volunteers
Accepted

Summary

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMCV44 doses of vaccine on Day 0, Day30, Day 60 and Month 12

Timeline

Start date
2024-06-12
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2024-04-29
Last updated
2025-08-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06389513. Inclusion in this directory is not an endorsement.